CHICAGO -- Transcatheter aortic valve replacement (TAVR) continued to hold its own against surgery for younger patients at low surgical risk, with the Evolut Low Risk trial now halfway to its goal ...

Transcatheter aortic valve replacement (TAVR) is a minimally invasive procedure used to replace damaged heart valves, ...

Medtronic plc’s Evolut Low-Risk trial continued to show non-inferiority of transcatheter aortic valve replacement to surgical aortic valve replacement in terms of death or disabling stroke at five ...

Medtronic plc, a global leader in healthcare technology, announced late-breaking data on five-year outcomes from the Evolut Low Risk Trial. Data shows, versus surgery, the Evolut transcatheter aortic ...

new data from the Evolut Low Risk Trial show. CHICAGO — Three months of dual antiplatelet therapy after PCI may safely balance thrombosis and bleeding risk in both patients with low and high ...

The Evolut Low Risk data presented today will help clinicians make personalized treatment decisions for younger, lower-risk patients by considering each patient's unique needs, now acknowledging ...